Last update May 13, 2019
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Phenazone is also known as
Phenazone in other languages or writings:
Phenazone belongs to these groups or families:
Main tradenames from several countries containing Phenazone in its composition:
|Protein Binding||< 10||%|
|Tmax||1 - 2||hours|
|T½||6 - 20||hours|
|Theoretical Dose||0.56 - 3.1||mg/Kg/d|
|Relative Dose||3.1 - 17.2||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
An analgesic and pyrazolone derivative which inhibits prostaglandin synthesis.
It has been used as an analgesic and systemic antipyretic but given the frequency and severity of its side effects, the majority of products currently on the market are made for dermatological or otological topical application.
Administered orally to mothers, it is excreted in breastmilk in amounts which could be significant (Berlin 1982).
Hemolytic anemia has been observed in a newborn whose mother was taking a phenazone derivative (Frei 1985).
Systemic use (orally) is contraindicated during breastfeeding.
The small dose and low plasma absorption of most topical dermatological and otic preparations make it unlikely that it will transfer into breastmilk in significant amounts.
Topical use is compatible with breastfeeding.